Thymosin alpha-1 is a peptide that has accumulated a clinical research record distinguishing it from many compounds in the longevity space that rest primarily on animal data. Understanding its benefits requires looking at what it actually does in the immune system, where the evidence is strongest, and what it does not do.

Thymosin alpha-1 is a 28-amino acid peptide found naturally in the thymus gland, the organ responsible for T-cell maturation. As we age, the thymus involutes, shrinks and loses function, and T-cell production declines. Thymosin alpha-1 appears to partially compensate for this age-related thymic decline by stimulating T-cell activity and enhancing immune surveillance.

The synthetic form, thymalfasin, is approved in 35 countries for treatment of hepatitis B, hepatitis C, and certain cancers. In the United States, it is available through compounding pharmacies under physician supervision.

The strongest evidence for thymosin alpha-1 is in infectious disease. Multiple randomized controlled trials have studied it in patients with chronic hepatitis B and hepatitis C, consistently showing improvements in viral clearance and immune response when combined with standard antiviral treatment.

Research in critically ill patients, particularly those with sepsis, has shown that thymosin alpha-1 treatment is associated with improved survival and reduced immune dysfunction. A 2019 multicenter study published in Frontiers in Immunology found that it improved T-cell function and reduced 28-day mortality in patients with severe sepsis.

Thymosin alpha-1 has been studied as an adjunct to cancer treatment in several contexts. It appears to enhance the activity of immune cells targeting tumor cells, and some research suggests it may reduce immune suppression caused by cancer therapies. While it is not a standalone cancer treatment, its role as an immunomodulatory adjuvant continues to be investigated.

The rationale for thymosin alpha-1 in longevity protocols comes from its documented ability to restore T-cell function in older adults. A study published in the Journal of Clinical Immunology found that administration increased natural killer cell activity and T-cell responsiveness in elderly subjects, mechanistically relevant because declining T-cell function is a well-documented feature of immune aging.

In clinical studies, thymosin alpha-1 has most commonly been used at 1.6 mg injected subcutaneously, either twice or three times weekly depending on the indication. Some longevity protocols use lower doses or less frequent administration. Administration is by subcutaneous injection, similar to how semaglutide is given. The peptide is well-tolerated in published literature, with injection site reactions being the most commonly reported side effect.

Any thymosin alpha-1 protocol should be supervised by a licensed physician who can individualize dosing based on your immune status, health history, and treatment goals.

The clinical evidence most directly supports thymosin alpha-1 for people with compromised immune function from chronic infection, cancer treatment, age-related immune decline, or specific immunodeficiency conditions. In the longevity context, it may be most relevant for older adults concerned about immune aging, frequent illness, or slow recovery from infection.

Despite its immune-supporting evidence, thymosin alpha-1 is not a cure for any condition, is not FDA-approved in the United States, and should not be purchased from unregulated sources. The quality and dosing accuracy of compounded peptides depends entirely on the compounding pharmacy's standards.


Individual results may vary. All prescriptions require approval by a licensed medical provider. Compounded medications are not FDA-approved. EllieMD facilitates access to independent healthcare providers and pharmacies and does not provide medical care or dispense medications.